TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable Hepatocellular Carcinoma

Objective: To retrospective analysis the efficacy and safety of Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC, Oxaliplatin + Raltitrexed) and systemic therapy in patients with unresectable Hepatocellular Carcinoma (uHCC). Methods: Clinical data of patients with uHCC who received TACE combined with Ralox-HAIC followed by sequential systemic therapy at our hospital between January 2023 and December 2024 were analyzed. The primary endpoint was Objective Response Rate (ORR). Secondary endpoints included Progression-Free Survival (PFS), Overall Survival (OS) and treatment safety. Results: A total of thirty-six patients with complete data were included. Efficacy evaluation showed: Complete Response (CR) in 6 cases (16.67%), Partial Response (PR) in 22 cases (61.11%), Stable Disease (SD) in 5 cases (13.89%), and Progressive Disease (PD) in 2 cases (5.56%). The ORR was 77.78%, and the Disease Control Rate (DCR) was 91.67%. The median PFS was 12.0 months, and the median OS was 19.0months. The one-year and two-year survival rates were 89% and 38%, respectively. No Grade 4 treatment-related adverse events or treatment-related deaths occurred. Conclusion: TACE combined with Ralox-HAIC and systemic therapy demonstrated a high ORR and DCR with manageable safety in uHCC, warranting further prospective studies for validation.